Search Results: kannalife (4)

The announcement comes shortly after it raised millions of dollars.
Here’s your daily round up of pot news, excerpted from the newsletter WeedWeek.
Vancouver-based grower Aurora Cannabis is planning a giant 600,000 square-foot grow in Alberta. That’s the size of 10 football fields. Canadian grower Aphria inked a deal to supply an Australian company with MED.
At least two large Canadian producers consider the  new federal home grow rules  “a setback for the advancement of sound cannabis policy.”
The Commodities Futures Trading Commission approved the first exchange for trading hemp derivatives.

Commons/Deerstock.


The Wolves of Wall Street may have paved their way to success and ultimately, a federal penitentiary by snorting copious amounts of cocaine and gang banging high-end prostitutes while running penny stock scams on blue-collar America, but these cash carnivores are preparing to sink their teeth into a new kind of green these days – legal marijuana.

Black Tie Magazine
Dean Petkanas, CEO, KannaLife: “Our exclusivity is narrowly focused”

Exclusive Interview: Dean Petkanas, CEO, KannaLife

(The Company Just Awarded An Exclusive Cannabinoid License By The Federal Government)

The exclusive rights to apply the cannabinoids found in marijuana as therapeutic agents awarded by the U.S. federal government to the firm KannaLife only apply to one specific medical condition, KannaLife’s CEO told Toke of the Town Monday night.

Dean Petkanas, chief executive officer at KannaLife Sciences, told us that the exclusivity applies only for the development and sale of cannabinoid based therapeutics as antioxidants and neuroprotectants for use in the treatment of hepatic encephalopathy.
“It is narrowly defined exclusivity, in that field,” Petkanas told us. “Our exclusivity is narrowly focused.”
Asked if KannaLife planned to get exclusive rights to develop cannabinoids to treat other conditions, Petkanas answered, “At the present time, we have no desire to do that.”

Medical Marijuana Hut

​The U.S. federal government’s Department of Health and Human Services seems about ready to award exclusive rights to apply marijuana as a medical therapeutic. You read that correctly: “exclusive rights.”

Now, I don’t think of myself as a conspiracy theorist. But when the federal government keeps taking actions that, even when considered separately but especially when viewed together, all seem to be part of a bigger plan to pave the way for the pharmaceutical industry to bulldoze the cottage medical marijuana industry, I start getting antsy.
“We find it hypocritical and incredible that on the one hand, the U.S. Department of Justice is persecuting cannabis patient associations, asserting that the federal government regards marijuana as having absolutely no medical value, despite overwhelming clinical evidence,” said Union of Medical Marijuana Patients director James Shaw. “On the other hand, the Department of Health and Human Services is planning to grant patent rights with possible worldwide application to develop medicine based on cannabis.”
“Though UMMP welcomes any potential new research that could come from KannaLife Sciences’ federal endorsement, it is highly disconcerting that the contemplated grant is an exclusive one,” the organization posted on its website.